"The objective of this advisory committee statement is to review the evidence for efficacy, effectiveness, immunogenicity and safety for LAIV use in HIV-infected individuals and to provide updated guidance on the use of LAIV in this population." - NACI recommendations on the use of LAIV and HIV-infected individuals
PDF
Bookmark
PDF
Program Delivery and Evaluation
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
Implementation Tool
Category
Program Planning and Delivery,Program Delivery and Evaluation,Clinics,Vaccine Preventable Diseases,Communicable Diseases,Influenza Program Planning and DeliveryProgram Delivery and Evaluation
Clinics
Vaccine Preventable Diseases
Communicable Diseases
Influenza
0 Comments
Using the comment box below, provide your feedback for this resource. Tell the immunization community how you used the resource, what worked, what didn't and the changes you made. The feedback provided will help inform the immunization community and improve upon the resource made available on CANVax.
All comments are anonymous. Submitted comments will be reviewed for approval by the CANVax team to ensure it meets content submission guidelines. Please note that although CANVax aims to approve comments in a timely manner, volume may result in delays.
You must login or register before you can submit a comment.